Screening of QHF formula for effective ingredients from Chinese herbs and its anti-hepatic cell cancer effect in combination with chemotherapy

作     者：CHEN Tao LI Dan FU Ya-ling HU Wei 

作者机构：Department of Traditional Chinese Medicine Three (Jorges University Medical College Yichang Hubei 443002 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2008年第121卷第4期

页      面：363-368页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：effective ingredients hepatic cell cancer uniform design QHFformula cisplatin 

摘      要：Background Recent studies have shown that effective ingredients of Chinese herbs are used more and more widely in the treatment or co-treatment of cancers, however, they are usually used separately and there has been limited research about joint application of Chinese herbs in multi-modal treatment. The aim of this study was to screen a QHF （Q： Qingrejiedu, H： Huoxuehuayu and F： Fuzhengguben） formula for effective ingredients from Chinese medicines and assess its anti-hepatic cell cancer （HCC） effect in combination with chemotherapy. Methods Six effective ingredients from Chinese medicine were selected based on the previous literature and used in the study. The QHF formula and the best ratio of ingredients were evaluated in H22 mouse （KM） models with solid tumors and ascites tumors by uniform design and monitoring inhibition of tumor growth and survival. We then observed the anti-hepatic cell cancer （HCC） effect of QHF when combined with cisplatin （DDP） in H22 mouse （Balb/c） models with solid tumors and ascites tumors. Evaluating of the therapeutic effect included the general condition of the mice, inhibition of tumor growth, survival, changes in body weight, thymus index, spleen index and WBC counts. Results The optimal QHF dose ratio for anti-hepatic cell cancer treatment was： 800 mg/kg Cinobufotalin, 14 mg/kg Ginsenosides Rg3, 5.5 mg/kg PNS and 100 mg/kg Lentinan. Treatment was more efficient in inhibiting the growth of transplanted tumors in H22 mice when using the QHF formula （55.91%） than using Cinobufotalin （33.25%）, Ginsenosides Rg3 （35.11%）, PNS （27.12%） or Lentinan （4.97%） separately. QHF also prolonged the life of H22 ascites hepatic cancer mice more efficiently （38.13%） than Cinobufotalin （25.00%）, Ginsenosides Rg3 （27.27%）, PNS （23.30%） or Lentinan （24.43%）. QHF combined with DDP could reduce DDP-induced leucopenia, spleen and thymus atrophy and other toxic reactions. Combining QHF with DDP the tumor growth inhibition reached 82.54% with a 66.83% incr